Literature DB >> 26375032

Transplacental Administration of Rosiglitazone Attenuates Hyperoxic Lung Injury in a Preterm Rabbit Model.

Jute Richter1, Jaan Toelen, Taro Nagatomo, Julio Jimenez, Jeroen Vanoirbeek, Jan Deprest.   

Abstract

INTRODUCTION: Continuous improvements in perinatal care have allowed the survival of increasingly more prematurely born infants. The establishment of respiration in an extremely immature yet still developing lung results in chronic lung injury with significant mortality and morbidity. We experimentally evaluated a novel medical strategy to prevent hyperoxia-induced lung injury by prenatal rosiglitazone.
MATERIALS AND METHODS: Pregnant rabbits were injected with saline or rosiglitazone (3 mg/kg) 48 and 24 h prior to preterm delivery at 28 days of gestation (term = 31 days). The pups were held in normoxia (21% O2) or hyperoxia (>95% O2), and assessment was done at three different time points (1 h, 24 h and 7 days).
RESULTS: The administration of rosiglitazone resulted in a significant decrease in tissue damping (resistance) on day 7. Furthermore, significantly increased expression of vascular endothelial growth factor, fetal liver kinase 1 and surfactant protein B immediately after delivery was noted by immunohistochemistery. On day 7, there was a more mature lung parenchymal architecture in rosiglitazone-exposed pups. DISCUSSION: In a preterm rabbit model, prenatal maternal administration of rosiglitazone attenuates neonatal hyperoxic lung injury and results in a more mature pulmonary parenchyma.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26375032     DOI: 10.1159/000439199

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  2 in total

1.  Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia.

Authors:  Giorgio Aquila; Yannick Regin; Xabier Murgia; Fabrizio Salomone; Costanza Casiraghi; Chiara Catozzi; Enrica Scalera; Matteo Storti; Francesca Stretti; Giancarlo Aquino; Giorgia Cavatorta; Roberta Volta; Carmelina Di Pasquale; Caterina Amato; Fabio Bignami; Davide Amidani; Barbara Pioselli; Elisa Sgarbi; Paolo Ronchi; Giuseppe Mazzola; Ignacio Valenzuela; Jaan Toelen
Journal:  Pharmaceutics       Date:  2022-07-20       Impact factor: 6.525

Review 2.  Oxygen toxicity: cellular mechanisms in normobaric hyperoxia.

Authors:  Ricardo Alva; Maha Mirza; Adam Baiton; Lucas Lazuran; Lyuda Samokysh; Ava Bobinski; Cale Cowan; Alvin Jaimon; Dede Obioru; Tala Al Makhoul; Jeffrey A Stuart
Journal:  Cell Biol Toxicol       Date:  2022-09-16       Impact factor: 6.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.